Nanotechnology-Enabled Personalized Medicine: Integrating Genetic, Epigenetic, and Metabolic Insights in Obesity and Type 2 Diabetes

Ngugi Mwaura J.

School of Natural and Applied Sciences Kampala International University Uganda

                                                                                                     ABSTRACT
Obesity and type 2 diabetes are heterogeneous, network-level disorders arising from the interplay of genetic variation, epigenetic remodeling, environmental exposures, and metabolic rewiring across adipose tissue, liver, skeletal muscle, gut, and pancreatic islets. Precision therapy requires not only stratifying patients by molecular drivers but also delivering interventions to the right tissue compartments with timing that reflects circadian and behavioral rhythms. Nanotechnology offers an enabling bridge between molecular diagnosis and actionable, patient-tailored treatment. Engineered nanoparticles like lipidic, polymeric, inorganic, or hybrid, can encapsulate diverse payloads, including small molecules, peptides, nucleic acids, and genome or epigenome editors, while incorporating ligands that target organ- and cell-specific receptors or microenvironmental cues. Meanwhile, minimally invasive diagnostics that harness circulating exosomes, cell-free nucleic acids, and
metabolomic signatures can guide endotype discovery and longitudinal monitoring. This review outlines a framework for nanotechnology-enabled personalized medicine in obesity and type 2 diabetes that integrates genomics, epigenomics, and metabolomics with smart delivery systems. We examine patient stratification using polygenic risk and epigenetic clocks, design rules for targeted and stimuli-responsive nanocarriers, and
strategies for aligning pharmacokinetics with metabolic states. Preclinical and emerging clinical evidence indicate that matching payload and carrier to molecular endotypes can amplify efficacy while reducing systemic exposure. We further discuss safety, manufacturability, regulatory science, and health equity considerations that determine feasibility at scale. By coupling molecular insight to programmable delivery, nanomedicine can move care beyond one-size-fits-all glycemic control toward durable network reprogramming tailored to each patient’s
biological context.

CITE AS: Ngugi Mwaura J. (2026). Nanotechnology-Enabled Personalized Medicine: Integrating Genetic, Epigenetic, and Metabolic Insights in Obesity and Type 2 Diabetes. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES.
https://doi.org/10.59298/NIJRMS/2026/7.1.5966